Abbott announced new analyses of the landmark COAPT Trial that show the company’s MitraClip device is cost effective and is projected to increase both life─expectancy and quality of life compared to guideline─directed medical therapy
Abbott announced new analyses of the landmark COAPT Trial that show the company’s MitraClip device is cost effective and is projected to increase both life─expectancy and quality of life compared to guideline─directed medical therapy
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
![Zonder mens geen merk: waarom AI nooit merkvertrouwen kan automatiseren [onderzoek]](https://www.pharmamarketeer.nl/wp-content/uploads/2025/11/206-80x60.jpg)